healthprotocol.wiki

di-pasquale_2003_rct_safety-and-tolerability-of-abciximab-in-patients-with-acute-myocardial-infarction-and-failed-thrombolysis

6 findings

Protocol
medication-abciximab-heparin-aspirin-thrombolysis-failed-acute-mi-generic
Outcome
safety-major-bleeding-events-count-cohort-measured
n
42
effect
-25
attribution
50
Protocol
medication-placebo-heparin-aspirin-thrombolysis-acute-mi-generic-protocol
Outcome
safety-major-bleeding-events-count-cohort-measured
n
42
effect
-15
attribution
50
Protocol
medication-abciximab-heparin-aspirin-thrombolysis-failed-acute-mi-generic
Outcome
vitals-cardiac-angina-events-30-day-count-reduction-measured
n
42
effect
40
attribution
55
Protocol
medication-abciximab-heparin-aspirin-thrombolysis-failed-acute-mi-generic
Outcome
vitals-cardiac-infarct-related-artery-patency-binary-angiography-measured
n
42
effect
85
attribution
70
Protocol
medication-abciximab-heparin-aspirin-thrombolysis-failed-acute-mi-generic
Outcome
vitals-cardiac-reperfusion-rapid-binary-noninvasive-measured
n
42
effect
85
attribution
65
Protocol
medication-placebo-heparin-aspirin-thrombolysis-acute-mi-generic-protocol
Outcome
vitals-cardiac-reperfusion-rapid-binary-noninvasive-measured
n
42
effect
0
attribution
75